SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) expects to make a final determination regarding the issuance of an operating license to SHINE by October 2021. SHINE’s application for a license to operate the medical isotope production facility that it is building in Janesville, Wis., was accepted and docketed by the NRC last October.
SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) has begun its detailed technical review of SHINE’s application to operate the medical isotope production facility the company is building in Janesville, Wis.
SHINE Medical Technologies LLC today announced that the company has filed an application with the U.S. Nuclear Regulatory Commission to produce medical isotopes, including molybdenum-99 (Mo-99), iodine-131 and xenon-133, at its production facility in Janesville, WI. SHINE broke ground on the facility in May of this year.
January 16, 2017 - SHINE Medical Technologies, Inc. (SHINE), a company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, held a ribbon cutting ceremony to celebrate the grand opening of the company’s new global headquarters in downtown Janesville, Wisconsin. The ribbon cutting was led by the John Beckord and the Forward Janesville Goodwill Ambassadors.